DiaMedica Therapeutics Inc. Common Stock/$DMAC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About DiaMedica Therapeutics Inc. Common Stock
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
Ticker
$DMAC
Sector
Primary listing
Employees
28
Headquarters
Website
DMAC Metrics
BasicAdvanced
$346M
-
-$0.69
1.40
-
Price and volume
Market cap
$346M
Beta
1.4
52-week high
$7.49
52-week low
$3.19
Average daily volume
297K
Financial strength
Current ratio
7.551
Quick ratio
7.337
Long term debt to equity
0.677
Total debt to equity
1.075
Profitability
EBITDA (TTM)
-31.418
Effective tax rate (TTM)
-0.09%
Management effectiveness
Return on assets (TTM)
-44.55%
Return on equity (TTM)
-73.41%
Valuation
Price to book
10.61
Price to tangible book (TTM)
10.61
Price to free cash flow (TTM)
-11.161
Free cash flow yield (TTM)
-8.96%
Free cash flow per share (TTM)
-0.599
Growth
Earnings per share change (TTM)
31.80%
3-year earnings per share growth (CAGR)
7.79%
10-year earnings per share growth (CAGR)
0.01%
What the Analysts think about DMAC
Analyst ratings (Buy, Hold, Sell) for DiaMedica Therapeutics Inc. Common Stock stock.
Bulls say / Bears say
DM199’s investigator-sponsored Phase 2 preeclampsia Part 1a interim results demonstrated highly statistically significant reductions in systolic and diastolic blood pressure, alongside no placental drug transfer, supporting its potential as a first-in-class therapy (Investing.com )
A $30.1 million private placement closed in July 2025 bolstered DiaMedica’s balance sheet, increasing pro forma cash to $67.2 million and funding operations into mid-2027 to support planned IND submissions and trial milestones (Investing.com )
Industry publication BioCentury highlighted DM199’s early efficacy in preeclampsia as rare progress in a therapeutic area with no approved treatments, underscoring the program’s differentiation and potential market leadership (BioCentury )
The ReMEDy2 Phase 2/3 acute ischemic stroke trial’s planned interim analysis on the first 200 participants is not expected until the second quarter of 2026, leaving investors with a prolonged wait for pivotal efficacy data and heightening uncertainty around the program’s timeline (Business Wire )
DiaMedica’s net loss widened to $15.4 million for the six months ended June 30, 2025 from $10.3 million a year earlier, driven by higher R&D and G&A expenses, accelerating cash burn ahead of key clinical readouts (SEC 10-Q )
The company’s forward-looking disclosures underscore significant dependency on successful outcomes of its DM199 clinical trials and regulatory approvals, highlighting execution and regulatory risk as the single-asset pipeline must perform to justify valuation (Business Wire )
Data summarised monthly by Lightyear AI. Last updated on 22 Oct 2025.
DMAC Financial Performance
Revenues and expenses
DMAC Earnings Performance
Company profitability
DMAC News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for DiaMedica Therapeutics Inc. Common Stock stock?
DiaMedica Therapeutics Inc. Common Stock (DMAC) has a market cap of $346M as of October 30, 2025.
What is the P/E ratio for DiaMedica Therapeutics Inc. Common Stock stock?
The price to earnings (P/E) ratio for DiaMedica Therapeutics Inc. Common Stock (DMAC) stock is 0 as of October 30, 2025.
Does DiaMedica Therapeutics Inc. Common Stock stock pay dividends?
No, DiaMedica Therapeutics Inc. Common Stock (DMAC) stock does not pay dividends to its shareholders as of October 30, 2025.
When is the next DiaMedica Therapeutics Inc. Common Stock dividend payment date?
DiaMedica Therapeutics Inc. Common Stock (DMAC) stock does not pay dividends to its shareholders.
What is the beta indicator for DiaMedica Therapeutics Inc. Common Stock?
DiaMedica Therapeutics Inc. Common Stock (DMAC) has a beta rating of 1.4. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.